OpenAI Unveils New Capabilities for GPT-Rosalind

OpenAI announced a new model update to the GPT-Rosalind series, designed for enterprise-scale life sciences research. This update combines GPT-5.5's agentic coding and tool-use capabilities with intelligence in core drug discovery domains such as medicinal chemistry and genetics, enhancing performance across life sciences analysis, design, and experimental workflows.

The new model has improved capability to synthesize data across various scales and modalities, including molecules, genes, pathways, and biological systems. This has demonstrated broad performance improvements in biology experts' research tasks, complex medicinal chemistry queries, quantitative biology, and wet lab troubleshooting.

To measure the model's practical impact, OpenAI introduced the expert-validated LifeSciBench benchmark. Unlike existing approaches that evaluate single components, this benchmark assesses six core workflows of life sciences research—evidence processing, analysis, design and optimization, scientific reasoning, validation and operations, and translation and communication—from an end-to-end perspective.

GPT-Rosalind is currently available as a research preview to eligible institutions worldwide through a trusted access structure.